Detail of "52479-85-3"

Reference

Psychopharmacological profile of the new cognition enhancing agent exifone in the mouse

Psychopharmacological profile of the new cognition enhancing agent exifone in the mouse. Porsolt, R. D.; Lenegre, A.; Avril, I.; Lancrenon, S.; Steru, L.; Doumont, G. (Lab. Rech., Inst. Tech. Etude Med., Paris, Fr.There are some reagents like 52479-85-3 is used in this study.). Arzneim.-Forsch., 37(4), 388-93 (English) 1987. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Adlone (exifone) (I) [52479-85-3], a novel compd. proposed for treating cognitive dysfunction in geriatric patients, was tested in a battery of std. psychopharmacol. tests in the mouse. The results indicated that the compd. was nontoxic and induced no signs of overt stimulation or sedation after acute administration of oral doses up to 1024 mg/kg. The compd. was devoid of anxiolytic, anticonvulsant or classical neuroleptic activity and did not antagonize the effects of reserpine or a high dose of apomorphine, 2 tests indicative of classical antidepressant activity. On the other hand, exifone clearly decreased the duration of immobility in the tail suspension test and antagonizded the hypothermia indiced by a low dose of apomorphine, 2 tests indicative of classical antidepressant activity. . The compd. shortened the duration of barbital-induced sleep without affecting the duration of sleep induced by pentobarbital. The effects obsd. suggest that exifone is not devoid of psychotropic activity and might possess some properties of an atypical antidepressant. .